GalaFlex Mesh in Facelift

May 15, 2023 updated by: C. R. Bard
In this post market study a resorbable mesh (GalaFLEX) will be used to reinforce the lifted and imbricated SMAS along the suture lines and spread the load of the SMAS along a greater surface area. GalaFLEX mesh is comprised of resorbable 4-hydroxybutyrate fibers.

Study Overview

Study Type

Observational

Enrollment (Actual)

15

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Ponte Vedra Beach, Florida, United States, 32083
        • Ponte Vedra Plastic Surgery
    • Illinois
      • Chicago, Illinois, United States, 60611
        • The Few Institute for Aesthetic Plastic Surgery
      • Chicago, Illinois, United States, 60612
        • Eye and Ear Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Primary Care Clinics

Description

Inclusion Criteria:

  • Subject is able to understand the risks and benefits of participating in the study and must be willing to sign and date the Informed Consent Form for this study approved by the Institutional Review Board (IRB.)
  • Be at least 21 years of age.
  • Be willing and able to comply with the requirements of the protocol.
  • Be willing to refrain from participating in any other investigational interventional study while enrolled in this study.
  • Female subjects must have a negative pregnancy test within the last 24 hours timeline and have no intentions of becoming pregnant during participation in the study, or be sterilized.

Exclusion Criteria:

  • Subject is unwilling or unable to give written consent to participate in the investigation or unable to comply with the requirements of the protocol.
  • Subject has known severe allergies manifested by a history of anaphylaxis, or history or presence of severe multiple allergies.
  • Subject has any serious skin disease, e.g., Eczema and psoriasis of the face, severe rosacea, scleroderma, local infections and severe acne.
  • Subjects has diabetes, coagulation disorders, connective tissue disorders, lipodystrophy, or other serious systemic disease.
  • Active herpes labialis
  • Subject is infected with HIV and/or received or may receive immunosuppressive therapy over the course of the study (such as rheumatoid arthritis).
  • Received any experimental drug or device within the previous three months.
  • Known alcohol or drug abuser.
  • Female subject who is pregnant or lactating or intending to become pregnant during the period of the study, or who would not use an adequate method of contraception (contraceptive pill, intra-uterine device) for the duration of the study.
  • Possesses any psychological condition, or is under treatment for any condition which, in the opinion of the Investigator and/or consulting physicians(s),would constitute an unwarranted risk.
  • Presents with severe jowling or severe cervical skin redundancy.
  • Subject is currently a smoker or is a prior smoker who quit in the last 12 months.
  • Active abscess or infection
  • Currently involved with claims for, or is accepting, workers compensation
  • Currently engaged in medical malpractice litigation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physician Satisfaction
Time Frame: 1 year
Investigator satisfaction will be judged by ease of product use, successful reinforcement, and total time for procedure to be completed.
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Satisfaction
Time Frame: 1 year
Patient satisfaction will be judged by the difference between pre- and post-surgery answers to Quality of Life questionnaires.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: Arikha Moses, Ph.D, Chief Scientific Officer, Founder

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2011

Primary Completion (Actual)

March 1, 2014

Study Completion (Actual)

June 1, 2014

Study Registration Dates

First Submitted

January 31, 2014

First Submitted That Met QC Criteria

January 31, 2014

First Posted (Estimate)

February 4, 2014

Study Record Updates

Last Update Posted (Actual)

May 16, 2023

Last Update Submitted That Met QC Criteria

May 15, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CP-1040

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Superficial Musculoaponeurotic System (SMAS) Procedure

3
Subscribe